{"transactions":[{"id":762640,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:14.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1630,"price":0.1743,"value":284.109,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 3,031 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 32,633 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":113654,"source":{"system":"sec-edgar","filing":"0002041855-26-000010","document":"form4-05272026_070509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000010/form4-05272026_070509.xml","form_type":"4"}},{"id":802121,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-04-23T20:07:12.000Z","date":"2026-04-22","kind":"sale","planned":false,"acquired":false,"shares":69827,"price":0.2534,"value":17694.1618,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2568, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":115284,"source":{"system":"sec-edgar","filing":"0002041855-26-000008","document":"form4-04232026_080406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000008/form4-04232026_080406.xml","form_type":"4"}},{"id":817526,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:16.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":225000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0002041855-26-000006","document":"form4-04032026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000006/form4-04032026_040407.xml","form_type":"4"}},{"id":880402,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:07.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":5119,"price":0.47,"value":2405.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 7,313 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 37,294 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":185111,"source":{"system":"sec-edgar","filing":"0002041855-26-000004","document":"form4-02262026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000004/form4-02262026_090201.xml","form_type":"4"}},{"id":880401,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:07.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":832,"price":0.4725,"value":393.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,190 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":190230,"source":{"system":"sec-edgar","filing":"0002041855-26-000004","document":"form4-02262026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000004/form4-02262026_090201.xml","form_type":"4"}},{"id":931449,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-01-26T21:08:45.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":7721,"price":0.3985,"value":3076.8185,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 2,022 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on May 30, 2025 under the Issuer's 2020 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person previously transferred 8 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse."}],"balance_after":191062,"source":{"system":"sec-edgar","filing":"0002041855-26-000002","document":"form4-01262026_090141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000002/form4-01262026_090141.xml","form_type":"4"}},{"id":987745,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-11-26T21:05:09.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.4166,"value":301.2018,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,298 shares from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 2,022 shares will vest on February 24, 2026, (b) 18,750 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":193791,"source":{"system":"sec-edgar","filing":"0002041855-25-000006","document":"form4-11262025_091103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185525000006/form4-11262025_091103.xml","form_type":"4"}},{"id":1013988,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:05.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.66,"value":4427.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 18,750 shares that will vest in successive equal quarterly installments through January 22, 2026, (b) 4,043 shares subject Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":194514,"source":{"system":"sec-edgar","filing":"0002041855-25-000004","document":"form4-10242025_051001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185525000004/form4-10242025_051001.xml","form_type":"4"}},{"id":1056122,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-08-27T00:03:33.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.5863,"value":423.8949,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,299 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 4,043 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 37,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":201222,"source":{"system":"sec-edgar","filing":"0001415889-25-023079","document":"form4-08272025_120830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925023079/form4-08272025_120830.xml","form_type":"4"}},{"id":1082406,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-07-24T20:55:05.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.4798,"value":3218.4984,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 37,500 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 6,065 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":201945,"source":{"system":"sec-edgar","filing":"0001415889-25-020242","document":"form4-07242025_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925020242/form4-07242025_080701.xml","form_type":"4"}},{"id":1132472,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:12.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.4733,"value":342.1959,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,298 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 6,065 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 56,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":208653,"source":{"system":"sec-edgar","filing":"0001415889-25-014696","document":"form4-05282025_040509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925014696/form4-05282025_040509.xml","form_type":"4"}},{"id":1166720,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-04-24T20:05:13.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.7763,"value":5207.4204,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 56,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":209376,"source":{"system":"sec-edgar","filing":"0001415889-25-011279","document":"form4-04242025_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925011279/form4-04242025_080410.xml","form_type":"4"}},{"id":1244033,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":99454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":99454,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":99454},"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244032,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":49726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":216084,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244031,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":507,"price":0.9561,"value":484.7427,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 911 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":166358,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244030,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":705,"price":1,"value":705.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,317 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 8,086 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 1,418 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":166865,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1295888,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:16.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":30456,"price":1.15,"value":35024.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 44,544 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 75,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 1,418 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 10,108 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 29, 2024 under the Issuer's 2020 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Since the date of the Reporting Person's last ownership report, he transferred 8,837 shares of common stock to his ex-spouse pursuant to a divorce agreement. The Reporting Person no longer reports as beneficially owned any securities transferred to his ex-spouse."}],"balance_after":167570,"source":{"system":"sec-edgar","filing":"0001415889-25-002022","document":"form4-01242025_040112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925002022/form4-01242025_040112.xml","form_type":"4"}},{"id":1351550,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2024-11-26T21:10:21.000Z","date":"2024-11-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":505,"price":1.94,"value":979.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares underlying the portion of an RSU grant that vested on November 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 25, 2024 of $1.94/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes: (a) 913 shares resulting from the November 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 1,418 shares will vest in one final installment on February 25, 2025, (b) 10,108 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."}],"balance_after":201863,"source":{"system":"sec-edgar","filing":"0001415889-24-027707","document":"form4-11262024_091117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588924027707/form4-11262024_091117.xml","form_type":"4"}},{"id":1351549,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2024-11-26T21:10:21.000Z","date":"2024-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":721,"price":1.88,"value":1355.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 22, 2024 of $1.88/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,300 shares resulting from the November 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 10,108 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 2,836 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":202368,"source":{"system":"sec-edgar","filing":"0001415889-24-027707","document":"form4-11262024_091117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588924027707/form4-11262024_091117.xml","form_type":"4"}}]}